GCG and type 2 diabetes mellitus: Although not a focus of this review, there is plentiful evidence that GLP-1 agonists protect from cerebral and peripheral insulin resistance as well as T2DM-associated hippocampal damage in vivo (see Gault and Holscher, 2018).